Cardiac arrhythmia is a common presenting complaint in adult patients with treated congenital heart disease. (CHD) Advances in surgical and electrophysiological intervention, combined with improved mechanistic understanding, mean that effective arrhythmia treatment is a realistic expectation for this challenging patient group. This short commentary outlines the current paradigm for arrhythmia management across the spectrum of adult congenital heart disease.
Advances in surgical technique over the last two decades have heralded a dramatic improvement in survival rates in those born with congenital heart disease (CHD). With current methods, more than 85% of paediatric patients undergoing surgical repair survive into adulthood, 1 and there are now at least 1.2 million people living in Europe with CHD, 2 of whom 50% are adults. These patients pose unique challenges to the cardiologists who treat them, and arrhythmias represent one of the leading causes of morbidity in this group. It is estimated that more than half of adults with severe CHD will experience atrial arrhythmia (AA) by the age of 65. 3 Despite the headline figures, there has been a general fall in prevalence of arrhythmia within lesion groups. This is likely to be related to the evolution of surgical procedures and the advent of catheter-based interventions, reducing surgical scar burden. However, 20% of hospital admissions in adults with repaired CHD continue to be arrhythmiarelated 4 and they represent a diverse group of patients who differ from the general population both in terms of the mechanism of their arrhythmia and its treatment with respect to catheter ablation.
The ongoing development of catheter-based technologies has made the treatment of arrhythmia in the congenital population an exciting, evolving and rewarding field.
The type and prevalence of arrhythmia in CHD varies according to congenital cardiac diagnosis and management course. In general though, the development of arrhythmias can be broadly attributed to: Many patients may initially be asymptomatic from their arrhythmia, potentially eluding timely diagnosis. However for some, particularly those with univentricular circulation, the onset of AA can precipitate rapid haemodynamic deterioration making prompt recognition and cardioversion of paramount importance.
Long-term management is often difficult, with pharmacological treatment rarely succeeding in achieving adequate arrhythmia control without substantial drug-related side-effects. Early catheter intervention should therefore be considered in all cases following a patient-specific evaluation of risk/benefit, and particularly for those in whom arrhythmia is associated with haemodynamic compromise. Use of fluoroscopic landmarks alone is generally not as reliable in this cohort as in the general population.
Once the arrhythmia mechanism has been identified, and the critical region accessed, radiofrequency (RF) energy remains the cornerstone of ablation. However, in specific circumstances cryoablation techniques offer theoretical advantages, due to enhanced catheter stability (cryoadhesion) and a potential period of reversible tissue injury before permanent destruction. This is particularly relevant for those with accessory pathways in difficult locations, such as Ebstein's anomaly, and those undergoing ablation of atrioventricular (AV) nodal re-entry tachycardia in whom the location of the AV node is displaced or unknown.
There is also likely to be a role for remote navigation systems including non-magnetic and magnetic navigation systems, the latter utilising highly flexible atraumatic catheters. Advantages of these systems include a potential reduction in total procedure and fluoroscopy time, whilst enabling stable navigation of the ablation catheter to locations that may be relatively inaccessible using conventional manipulation techniques. 8, 9 In terms of procedural success rates, analysis of existing paediatric registries relating to catheter ablation would suggest that the presence of CHD does not impact significantly on acute outcome rates 10, 11 with an overall procedural failure rate of only 7.5%. Nevertheless, data are scarce, particularly relating to long term outcomes. To this end
The Multicentre Pediatric and Adult Congenital EP Quality Initiative 12 registry was established in 2010 with the expectation of providing long term data on the status of catheter ablation in the CHD population.
The results of large scale initiatives such as these are likely to provide a vital insight into optimal patient management.
In summary, every patient with CHD-associated arrhythmia presents a new challenge and the potential benefits of successful treatment may be life-changing or even life-saving. We need to strive to integrate detailed understanding of the patient anatomy and arrhythmia substrate with the most appropriate technologies to give every chance of treatment success. Arrhythmia in CHD will continue to grow over the next 30 years, and the continuing evolution of reliable treatment modalities will have a profound impact on long-term outcome for this patient group. ■
